Understanding Metastatic Uveal Melanoma

Uveal melanoma, the most prevalent primary intraocular malignancy in adults, originates from melanocytes within the uvea, the eye’s middle layer. When this cancer spreads, typically to the liver, it becomes metastatic uveal melanoma, a particularly aggressive and difficult-to-treat form. Historically, treatment options have been limited, resulting in a poor prognosis for affected individuals. According to the American Cancer Society, the five-year survival rate for uveal melanoma that has spread to distant sites is unfortunately low, underscoring the urgent need for more effective therapies.

Percutaneous Liver Infusion: A Targeted Approach

A recent international clinical study, spearheaded by the Moffitt Cancer Centre, investigated the potential of percutaneous liver infusion to deliver chemotherapy directly to liver metastases in patients with metastatic uveal melanoma. This method allows for a concentrated dose of medication to be administered precisely where its needed, minimizing systemic side effects. Percutaneous liver infusion is a specialized technique where chemotherapy, frequently enough at high concentrations, is delivered directly to the liver to combat tumors or metastases, offering a targeted choice to customary systemic chemotherapy.

The FOCUS Trial: Key Findings

The phase 3 FOCUS clinical trial,the results of which were published in the journal Annals of Surgical Oncology,compared percutaneous liver infusion of the chemotherapy drug Melfalan against standard treatment protocols for metastatic uveal melanoma.The results demonstrated a significant improvement in outcomes for patients receiving the liver infusion therapy.

Improved Progression-Free Survival

Patients treated with percutaneous liver infusion experienced a median progression-free survival of 9.1 months, a ample increase compared to the 3.3 months observed in the control group receiving standard treatment. This indicates a significantly longer period during which the cancer did not worsen.

Enhanced Tumor Control

The objective response rate,reflecting the percentage of patients whose tumors shrank or disappeared,was 27.5% in the liver infusion group, nearly three times higher then the 9.4% in the control group. Moreover, the disease control rate, encompassing patients with stable disease along with those with tumor shrinkage, rose dramatically from 46.9% to 80.0%.

Overall Survival Benefit

while the study also tracked overall survival, patients treated with the hepatic administration system lived an average of 18.5 months, compared to 14.5 months in the conventional treatment group. Although adverse reactions,primarily related to blood cell count decreases,were observed,they were generally manageable on an outpatient basis and resolved with monitoring.

Expert Viewpoint

According to Dr. Jonathan Zager, a surgical oncologist at Moffitt Cancer Center and lead author of the study, This new treatment offers hope for patients with a recognized cancer for the difficulty of its management. He emphasized that the study’s findings demonstrate the ability of the new treatment system to effectively control the disease within the liver.

It is a therapeutic option that does not compromise the quality of life of patients and gives them the chance of prolonged survival.

Dr. Jonathan Zager, Moffitt Cancer Center

The targeted nature of percutaneous liver infusion, delivering high doses of medication directly to the liver while minimizing systemic exposure, is a key advantage. By temporarily isolating the liver with catheters and balloons, the drug is filtered before entering general circulation, reducing toxicity.

Future Directions

The research team is actively planning further studies to comprehensively evaluate the benefits of percutaneous liver infusion and explore its potential in combination with other emerging cancer therapies. This ongoing research aims to refine treatment strategies and further improve outcomes for patients with metastatic uveal melanoma.